About

Patricia Zilliox, who joined the Eyevensys board in May 2016 and became Chief Executive Officer in December 2017, has three decades’ experience of global clinical development in ophthalmology.

Prior to Eyevensys, Dr Zilliox served as Chief Drug Development Officer of the Clinical Research Institute, a division of the Foundation Fighting Blindness, Columbia, MD, US, where she led the financing of several start-ups in the field of gene therapy.

She also spearheaded validation of a new clinical endpoint in the field of retinitis pigmentosa, opening the path for drug developers to focus on treatment of this rare condition of the retina. Previously, Dr Zilliox held several positions at Alcon/Novartis, including head of clinical development for ophthalmology.

Contributions

OCULAR

CREATING SUSTAINABLE BIOTHERAPEUTICS FACTORIES IN THE EYE

Patricia Zilliox discusses the inherent difficulties in drug delivery to the back of the eye and how this creates an unmet need in ophthalmology. Dr Zilliox goes on to describe Eyevensys’ novel solution to this problem, and the company’s first lead product, EYS606.